Type to search

Amniotics AB Announces Positive Pre-clinical Proof-of-concept Results for PulmoStem™ in End-stage Lung Disease | Pharmtech Focus
Stem Cell Therapy Company Amniotics Raises SEK 60 Million Before Deduction of Transaction Costs, in First North IPO to Advance Lead Candidate PulmoStem™ into Clinic | Pharmtech Focus